BTAI Earnings Prediction
The chart below shows how BTAI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BTAI sees a +18.36% change in stock price 10 days leading up to the earnings, and a -7.53% change 10 days following the report. On the earnings day itself, the stock moves by -4.39%. This data can give you a slight idea of what to expect for the next quarter's release.
BTAI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
214.00K
-37.24%
-80.62%
Gross Margin
-446.73%
790.79%
-573.33%
Operating Margin
-6420.56%
-50.39%
331.16%
Net Margin
-6378.50%
-56.92%
748.52%
EPS
-0.32
-81.40%
52.38%
No Data Available
BTAI Earnings Analysis
BioXcel Therapeutics, Inc. Common Stock Corporation (BTAI.O) Earnings Conference Call
Positive
Net Revenue Comparison: Net revenue for IGAIM was $214,000 for the third quarter of 2024, compared to $341,000 for the same period in 2023.
Net Revenue Surge: The net revenue of $1.9 million for the nine months ended September 30, 2024, represents an 89% increase from $1 million in the same period in 2023.
Customer Acquisition Growth: The increase in new customer acquisitions and increased sales activity reflects rising utilization.
R&D Expense Decrease: Research and development expenses were $5.1 million for the third quarter of 2024, compared to $19.6 million for the same period in 2023, indicating a decrease in expenses.
Cost Reduction Achievement: Selling, general, and administrative expenses were $7.7 million for the third quarter of 2024, compared to $24.3 million for the same period in 2023, showing a significant reduction in costs.
Negative
Net Revenue Decline: Net revenue for IGAIM was $214,000 for the third quarter of 2024, compared to $341,000 for the same period in 2023, indicating a significant decrease in sales.
Net Loss Comparison: The company reported a net loss of $13.7 million for the third quarter of 2024, compared to a net loss of $50.5 million for the same period in 2023, reflecting ongoing financial challenges.
R&D Expense Reduction: Research and development expenses were $5.1 million for the third quarter of 2024, compared to $19.6 million for the same period in 2023, indicating a substantial reduction in investment in this area.
Cost Reduction Impact: Selling, general, and administrative expenses were $7.7 million for the third quarter of 2024, compared to $24.3 million for the same period in 2023, showing a drastic cut in operational costs but potentially impacting growth.
Rising Production Costs: Cost of goods sold for the three months ended September 30, 2024, was $1.2 million, compared to $512,000 for the same period in 2023, indicating rising production costs.
BTAI FAQs
How does BTAI typically perform around its earnings report dates?
Is BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BTAI Earning Call Sentiment
BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BTAI.O
-5.12%Positive
The earnings call highlights financial strain with declining IGALMI revenue, a significant net loss, and increased COGS due to inventory issues. Although R&D and other expenses have decreased, the company faces regulatory risks and competitive pressures. The Q&A section reveals management's lack of clarity on FDA feedback and financial sufficiency, which raises concerns. Despite some progress in trials and reduced losses, the absence of a shareholder return plan and unclear guidance suggest a negative market reaction.
